Jupiter Neurosciences, Inc. Common Stock
Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, develops resveratrol platform products for the treatment of neuroinflammation. The company develops JNS101, which is in Phase II trial for the treatment of Friedreich's Ataxia, a rare inherited disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS108 that is in Phas… Read more
Jupiter Neurosciences, Inc. Common Stock (JUNS) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -20.106x
Based on the latest financial reports, Jupiter Neurosciences, Inc. Common Stock (JUNS) has a cash flow conversion efficiency ratio of -20.106x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.15 Million) by net assets ($57.42K). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Jupiter Neurosciences, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Jupiter Neurosciences, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Jupiter Neurosciences, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Jupiter Neurosciences, Inc. Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Ruchi Infrastructure Limited
NSE:RUCHINFRA
|
0.089x |
|
HF COMPANY INH. EO -50
F:HFC
|
N/A |
|
Fortuna Metals Limited
AU:FUN
|
-0.058x |
|
Mycodern S.A.
F:GY3
|
N/A |
|
Inter-Rock Minerals Inc
PINK:IRCKF
|
0.238x |
|
Enduro Metals Corporation
OTCQB:ENDMF
|
-0.023x |
|
Aman Agrindo
JK:GULA
|
-0.080x |
|
Lumos Diagnostics Holdings Limited
PINK:LDXHF
|
0.149x |
Annual Cash Flow Conversion Efficiency for Jupiter Neurosciences, Inc. Common Stock (2019–2024)
The table below shows the annual cash flow conversion efficiency of Jupiter Neurosciences, Inc. Common Stock from 2019 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $4.17 Million | $-3.91 Million | -0.937x | -1230.76% |
| 2023-12-31 | $-5.80 Million | $-480.95K | 0.083x | -52.56% |
| 2022-12-31 | $-7.14 Million | $-1.25 Million | 0.175x | -47.85% |
| 2021-12-31 | $-5.18 Million | $-1.74 Million | 0.335x | +388.09% |
| 2020-12-31 | $-3.71 Million | $-254.78K | 0.069x | +140.91% |
| 2019-12-31 | $-5.02 Million | $-142.95K | 0.028x | -- |